DURECT Corporation - Special Call Transcript
All right. It looks like it's mostly there. Hi everyone. I'm Ellie Merle. I'm one of the biotech analysts here at Cantor. Very happy to have DURECT Corporation with us here today to talk about their programs in alcoholic hepatitis, a range of other liver diseases as well as COVID as well as discuss POSIMIR for post-surgical pain. Very happy to have with us here today James Brown, President and Chief Executive Officer; Michael Arenberg, Chief Financial Officer; and WeiQi Lin, Executive Vice President of Research & Development and Principal Scientist. Thank you guys so much for joining us. Really appreciate the time.
Questions & Answers
And I guess to kick it off, maybe just to sort of frame the discussion for background, you guys have a sort of long corporate history focused on drug delivery devices. And now you're developing DUR-928, which is a novel epigenetic
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |